Abstract
Background
Diabetic nephropathy (DN) is a clinical syndrome occurring in patients with diabetes mellitus, that is characterized by persistent albuminuria, worsening proteinuria, hypertension, and progressive renal failure [1] . Approximately a third of patients with type 1 insulin-dependent diabetes mellitus (T1DM) and type 2 non-insulin-dependent diabetes mellitus (T2DM) develop diabetic nephropathy (DN) [2] .
From a clinical point of view, diabetic nephropathy (DN) behaves as a progressive disease process that advances through characteristic phases. It begins with microalbuminuria (leakage of small amounts of albumin into the urine), slowly progressing towards overt proteinuria [3] [4] [5] .
Genetic studies have revealed that the genes of Renin-Angiotensin-System (RAS) are highly polymorphic, raising the possibility that in addition to environmental factors, the genetic make up of RAS affects the status of -RAS in individuals. One of such is the insertion/deletion polymorphism of ACE (ACE I/D) gene [6] . Studies of familial clustering have consistently demonstrated that genetic susceptibility plays an important role in diabetic nephropathy [7] and the gene encoding ACE is a potential candidate gene in its etiology. ACE gene has been described with an I/D polymorphism of a 287 bp in intron 16 [8] , leading to three genotypes, DD and II homozygotes and ID heterozygote. The mean plasma/serum ACE level in the DD subjects is reported to be approximately double that of II subjects, with ID subjects having intermediate values [9] .
In a pioneering study, Marre et al. proposed a protective effect of the II genotype against the development of diabetic nephropathy in T1DM [10] . Thereafter, a sizeable number of association studies have investigated the possible role of ACE I/D polymorphism in the pathophysiology of diabetic nephropathy and most of them have recorded association of the D allele as a risk factor [11] [12] [13] [14] .
Material and methods
Subjects and clinical data. 416 type 1 diabetes mellitus patients afferent to Pediatrics, Nephrology and Diabetes outpatient Clinics of the San Raffaele Hospital (Italy) were enrolled in the study.
Patients who gave their written informed consent to participate fulfilled the following criteria: men or women with T1DM for 3 or more years, aged < 40 years at the onset of diabetes, no chronic disease unrelated to diabetes. Patients were then divided in two groups:
1. Type 1 diabetic patients without nephropathy (T1DM), normoalbuminuric, with serum creatinine lower than 1.2mg/dL and creatinine clearance greatest than 70mL/min).
2. Type 1 diabetic patients with severe diabetic nephropathy (T1DN), defined as serum creatinine greater than 1.2mg/dL and creatinine clearance lower than 70ml/min, with concomitant diabetic retinopathy. Patients with T1DN had diabetes >10 years prior the onset of proteinuria.
The study involved outpatient visits scheduled every 6 to 12 months for the measurement of weight, BP, glycated hemoglobin (HbA1c), plasma total cholesterol, triglycerides and creatinine. Body mass index (BMI) was calculated as weight in kilograms divided by squared height in meters. The local Ethic Committee approved the study protocol.
Renal and biochemical parameters. Estimated glomerular filtration rate (eGFR) has been computed for each patient using the CKD-EPI formula [15] . The rate of progression towards ESRD has been computed separately for each patient and expressed as loss of GFR per year (expressed as ml/min -1 /year -1 ) indicated as slope [16] .
Biochemical parameters such as lipidic profile and creatinine, were measured at least every 6 months in the outpatient clinic, immediately after sampling when appropriate. Glycated haemoglobin (HbA1c) was measured by HPLC analysis and the mean of the last three years (at least two measurements per year) was used to define the glycemic control. Genotyping. DNA was extracted from venous whole blood using a salting out procedure according with Maniatis et al. (1989) [17] .
DNA was amplified by PCR using three oligonucleotide primers in a single reaction. Two primers flanked the insertion-deletion site (5'-CTGGAGACCACTCCCATCCTTTCT-3'and 5'-GATGTGGCCATCACATTCGTCAGAT-3') and generated a product of 190bp from D alleles, and a product of 490bp from I alleles. Due to preferential amplification of D allele, the 490bp band is not always visible in heterozygous samples. To avoid the misidentification of ID heterozygotes, a third primer complementary to sequence within the insertion was included in all reaction (5'-TGGGATTACAGGCGTGATACAG-3') [18] . This consistently generated a fragment of 159bp from I alleles only. The 159 and 190bp fragments were used for genotyping.
Amplification reactions were carried out in a total volume of 20µl, using 10ng genomic DNA (2µl), 0.32µl MgCl 2 (0.8mM), 2µl NH 4 buffer1X , 0.4µl dNTPs (0.2mM), 0.8µl of each primer (80ng/µl) and 0.2µl of Taq polymerase (1U/µl). Samples were denatured at 96ºC for 5 min, followed by 34 cycles of denaturation at 94ºC for 30s, primer annealing at 58ºC for 1 min and DNA extension at 72ºC for 1 min, with a final 10 min extension stage at 72ºC.
Detection of ACE I/D polymorphism by electrophoresis. The reaction products were separated by electrophoresis in 2% agarose gel and stained with ethidium bromide. Under ultraviolet light three bands were visible: 159bp band (genotype II), 190bp band (genotype DD) or both (genotype ID) ( Figure 1) .
Statistical analysis. The SPSS statistical software package version 20 (IBM, US) was used for the statistical analyses. Data are expressed as mean ± standard deviation. Genotype and allele frequencies of ACE gene polymorphism were compared between type 1 diabetic patients with and without nephropathy using chi-square analysis. Twotailed Student's t-test was also used to compare quantitative data. Statistical significance was assumed at the P<0.05 level. 
Results
We analysed a total of 416 patients, divided in 2 groups: T1DM and T1DN. The T1DM group contained 237 patients (111 women and 126 men) while the T1DN group had 179 patients (61 women and 118 men).
Clinical characteristics of each group are shown in Table 1 . Of course the majority of parameters examined were different between the two groups, as expected by the natural history of DN. The mean of diabetes duration was 21 years (range 5-48) for T1DM, and 27 (range 6-51) for T1DN. As expected, patients with nephropathy were older, with higher levels of BP (both systolic and diastolic), more severe metabolism alterations (cholesterol and triglycerides elevated), and lower values of eGFR. Only HbA1c was higher in T1DM group compared to T1DN group. The p-value between the parameters is reported in Table 1 . Values are mean ± SD; n.s.= not significant. BMI= body mass index (kg/m²); SBP= sistolic blood pressure (mmHg); DBP= diastolic blood pressure (mmHg); HbA1c= glycated hemoglobin (%); eGFR= estimate glomerular filtration rate (ml/min/1.73 m2).
For the following statistical analysis patient values were corrected for gender, age, duration of diabetes, blood pressure, biochemical parameters, HbA1c and eGFR. The velocity of progression of nephropathy (slope) was calculated as follows: [(1/creatinine t 1 -1/creatinine t 0 )/T], where t 0 is the inverse of creatinine at the last visit, t 1 is the inverse of creatinine at the first visit and T the time interval between the first and the last visit. This parameter allows to evaluate the time spanning the begin of the T1DM and the T1DN onset. Values are mean ± SD. n.s.= not significant p value. N= number of cases. eGFR= estimate glomerular filtration rate (ml/min/1.73 m2).
Patients grouped according to ACE I/D genotypes are shown in Table 2 . In each study group, the genotypic frequency distributions of this polymorphism were in HardyWeinberg equilibrium. In our study ID genotype was the most frequent, present in 49.79% (T1DM) and 47.49% (T1DN), followed by DD in 30.8 % (T1DM) and 38.55% (T1DN) and II was found in only 19.41% (T1DM) and 13.97 % (T1DN). Although there is a difference in DD genotype frequencies between the two groups of patients, statistical analysis indicates a p value >0.05, showing that there is no association between D or I ACE alleles and diabetic nephropathy.
We evaluated the association among slope and clinical parameters available for each genotype. We observed significant association with cholesterol (only DD genotype), triglycerides and GFR (II, ID and DD genotypes). Also analyzing the association of GFR, as a determinant of DN progression, with other investigated parameters, we observed in patients with DD genotype most significant correlations, including HbA1c (p = 0.023). HbA1c appears to influence the DN progression only in patients with DD genotype. In patients with ID and DD genotypes HbA1c is not associated with GFR. Also, regardless of the initial or final GFR value, patients with genotype DD present the lowest values of slope (Table 3) .
Considering all these data, it appears that in ID and DD patients we have the most risk factors in relation to slope and GFR, that are considered determinant markers of DN progression. These results indicate that the D allele could be considered a risk factor for ND progression, related with other potential factors (genetic, environmental, etc.) in the studied population.
Discussion
The RAS serves as one of the most powerful regulators of arterial blood pressure and could be considered a good candidate involved in the pathogenesis of diabetic renal complication [19] . The ACE is an important part of the RAS, which is a complex regulatory network with intrinsic as well as extrinsic agonistic and antagonistic hormones. It had increasingly been recognized that ACE inhibition exerts organ protective effects probably even beyond its antihypertensive potential in diabetic renal disease [20, 21] .
We examined I/D polymorphism of the ACE gene, one of the important genes in RAS, in T1DM patients with and without nephropathy. The primary objective of the study was to find the distribution pattern of ACE I/D polymorphism in T1DM and T1DN and to discover the relationship between DD genotype and DN. Our results show that there is no association between ACE I/D polymorphism and T1DM or T1DN. In particular, the DD genotype, which has previously been implicated in both type 1 [13] and 2 [22] diabetes is not associated with an increased risk of developing diabetic nephropathy. The reason of the difficulty in finding positive results may be that, the effect of ACE genotype must be studied in experimental settings that takes into account the appropriate combination of interacting alleles of other susceptibility gene.
A number of pathophysiological studies has been performed that may allow to discern the functional role of ACE I/D polymorphism [6, 12, 13] . The studies conducted so farlead to contradictory results. To answer this question, we have to consider the potential interaction with other relevant genetic factors. Therefore in the near future we want to focus on other genetic polymorphisms and evaluate the possible involvement in the evolution and progession of ND.
Our study showed that the D allele did not associate with T1DN. In conclusion, this study showes that DD genotype and D allele alone in type 1 diabetic patients with and without nephropathy did not influence the occurrence of this dissorder.
